Cargando…

The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial

INTRODUCTION: Type 2 diabetes mellitus (T2DM) is a strong risk factor for coronary artery disease and heart failure, particularly heart failure with preserved ejection fraction (HFpEF). The aim of the ongoing MUSCAT-HF (It stands for Prospective Comparison of Luseogliflozin and Alpha-glucosidase on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ejiri, Kentaro, Miyoshi, Toru, Nakamura, Kazufumi, Sakuragi, Satoru, Munemasa, Mitsuru, Namba, Seiji, Takaishi, Atsushi, Ito, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475163/ https://www.ncbi.nlm.nih.gov/pubmed/30928954 http://dx.doi.org/10.1136/bmjopen-2018-026590

Ejemplares similares

Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus
por: Ejiri, Kentaro, et al.
Publicado: (2020)

Correction: The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial
Publicado: (2019)

Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure
por: Ejiri, Kentaro, et al.
Publicado: (2022)

Tobacco smoking protective effect via remote ischemic preconditioning on myocardial damage after elective percutaneous coronary intervention: Subanalysis of a randomized controlled trial
por: Ejiri, Kentaro, et al.
Publicado: (2018)

Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: Secondary analysis of a randomized, controlled trial (RINC)
por: Kawakita, Norifumi, et al.
Publicado: (2018)

Muscat
Publicado: (1876)

High Plasma Docosahexaenoic Acid Associated to Better Prognoses of Patients with Acute Decompensated Heart Failure with Preserved Ejection Fraction
por: Matsuo, Naoaki, et al.
Publicado: (2021)

Fibrosis‐4 index reflects right ventricular function and prognosis in heart failure with preserved ejection fraction
por: Nakashima, Mitsutaka, et al.
Publicado: (2021)

Luseogliflozin preserves the pancreatic beta-cell mass and function in db/db mice by improving mitochondrial function
por: Yamauchi, Yuki, et al.
Publicado: (2022)

Noninvasive imaging assessment of rehabilitation therapy in heart failure with preserved and reduced left ventricular ejection fraction (IMAGING-REHAB-HF): design and rationale
por: Cardoso, Fernando Bianchini, et al.
Publicado: (2019)

Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan
por: Naito, Takanori, et al.
Publicado: (2023)

MUSCAT: The muon scattering experiment
por: Attwood, D, et al.
Publicado: (2000)

Rationale and design of the preserved versus reduced ejection fraction biomarker registry and precision medicine database for ambulatory patients with heart failure (PREFER-HF) study
por: Abboud, Andrew, et al.
Publicado: (2021)

Differences in extracellular fluid volume between acute heart failure patients with and without high systolic blood pressure
por: Namba, Yusuke, et al.
Publicado: (2022)

Comparable effect of aliskiren or a diuretic added on an angiotensin II receptor blocker on augmentation index in hypertension: a multicentre, prospective, randomised study
por: Miyoshi, Toru, et al.
Publicado: (2017)

The PARAGON-HF trial: the sacubitril/valsartan in heart failure with preserved ejection fraction
por: Gronda, Edoardo, et al.
Publicado: (2020)

Rationale for the Use of Pirfenidone in Heart Failure With Preserved Ejection Fraction
por: Graziani, Francesca, et al.
Publicado: (2021)

Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
por: Lewis, Gregory D., et al.
Publicado: (2023)

Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus
por: Nakamura, Kazufumi, et al.
Publicado: (2022)

Effects of luseogliflozin treatment on hyperglycemia-induced muscle atrophy in rats
por: Xie, Keyu, et al.
Publicado: (2023)

Clients’ Satisfaction with Primary Health Care in Muscat
por: Albalushi, Rima M, et al.
Publicado: (2012)

The Heart Failure Optimization Study (HF-OPT): rationale and design
por: Sanchez, R., et al.
Publicado: (2023)

Current Treatment Strategies and Nanoparticle-Mediated Drug Delivery Systems for Pulmonary Arterial Hypertension
por: Nakamura, Kazufumi, et al.
Publicado: (2019)

Constructability practices in construction industry in Muscat: case study
por: Al Hamadani, Said, et al.
Publicado: (2022)

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
por: Lund, Lars H., et al.
Publicado: (2021)

Sacubitril/valsartan and loop diuretic requirement in heart failure with preserved ejection fraction in the PARAGON‐HF trial
por: Chatur, Safia, et al.
Publicado: (2022)

Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial
por: Lewis, Gavin A., et al.
Publicado: (2019)

Sacubitril/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Effect of the sodium–glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages
por: Takahashi, Kiyohiko, et al.
Publicado: (2018)

Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF)
por: Parikh, Riya R, et al.
Publicado: (2022)

Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension
por: Nakamura, Kazufumi, et al.
Publicado: (2017)

Heart failure with preserved ejection fraction (HFpEF) pathophysiology study (IDENTIFY-HF): does increased arterial stiffness associate with HFpEF, in addition to ageing and vascular effects of comorbidities? Rationale and design
por: Ali, Danish, et al.
Publicado: (2019)

Prognostic value of heart failure echocardiography index in HF patients with preserved, mid-ranged and reduced ejection fraction
por: Chen, Jian-Shu, et al.
Publicado: (2020)

The complete chloroplast genome sequence of Vitis vinifera Muscat Hamburg
por: Guo, Dinghan, et al.
Publicado: (2019)

The first multicentre study on coronary anomalies in the Netherlands: MuSCAT
por: Koppel, C. J., et al.
Publicado: (2021)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study
por: Nakamura, Kazufumi, et al.
Publicado: (2014)

Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials
por: Nassif, Michael E., et al.
Publicado: (2023)

Heart failure prevalence in the general population: SOBOTA‐HF study rationale and design
por: Lainscak, Mitja, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_i4esj10744jc70aj0vv686i2rf